One pivotal study demonstrated that activating ferroptosis can alleviate cisplatin resistance in gastric cancer cells by inhibiting the Nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1/Cystine/glutamate transporter (Nrf2/Keap1/xCT) signaling pathway. This evidence concerns the gene NFE2L2 and gastric cancer.